Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risperidone in pervasive developmental disorders.

Craig A Erickson1, Kimberly A Stigler, David J Posey

  • 1Riley Hospital, Child and Adolescent Psychiatry Clinic, 702 Barnhill Drive, ROC 4300, Indianapolis, IN 46202, USA. crericks@iupui.edu

Expert Review of Neurotherapeutics
|November 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FMR1 gene therapy restores translationally relevant phenotypes in a mouse model for fragile X syndrome.

Gene therapy·2026
Same author

Gaboxadol increases resting theta and alpha power without affecting evoked responses in fragile X syndrome in a home-based setting.

Journal of neurodevelopmental disorders·2026
Same author

Quantifying vocal subsystems of adults with minimally verbal autism spectrum disorder.

Frontiers in human neuroscience·2026
Same author

SPG601-associated modulation of resting-state EEG and improvement in executive function in a fragile X syndrome randomized controlled crossover study.

Scientific reports·2026
Same author

Acute and chronic dosing of the GABA A alpha 2,3 selective agonist BAER-101 do not alter behavior but may impact auditory-evoked EEG responses in adults with fragile X syndrome.

Scientific reports·2026
Same author

Prenatal antiseizure drug exposure and risk of neurodevelopmental disorders in children: population based cohort study.

BMJ (Clinical research ed.)·2026

Risperidone is a key atypical antipsychotic for managing severe behavioral disturbances in pervasive developmental disorders. This review details its use, effects, and monitoring strategies for this population.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Developmental Disorders

Background:

  • Atypical antipsychotics are increasingly prescribed for severe behavioral disturbances in individuals with pervasive developmental disorders.
  • Risperidone is the most extensively researched medication in this class for this patient group.

Purpose of the Study:

  • To provide a comprehensive drug profile of risperidone for pervasive developmental disorders.
  • To review available data on risperidone's efficacy, safety, and use in this population.

Main Methods:

  • Literature review of studies on risperidone in pervasive developmental disorders.
  • Analysis of risperidone's chemistry, pharmacokinetics, pharmacodynamics, and metabolism.
  • Emphasis on adverse effects and monitoring strategies.

Related Experiment Videos

Main Results:

  • Risperidone is a widely studied option for behavioral disturbances in pervasive developmental disorders.
  • The review covers essential pharmacological aspects and clinical data.
  • Adverse effects and monitoring protocols are detailed.

Conclusions:

  • Risperidone is a significant therapeutic option for pervasive developmental disorders with severe behavioral disturbances.
  • Understanding its profile, including adverse effects, is crucial for effective patient management.
  • Future directions and key considerations for risperidone use are discussed.